Obesity, Type 2 Diabetes Mellitus
Conditions
Keywords
Brown Adipose Tissue, Weight, Sympathetic Nervous System
Brief summary
In this study the investigators aim to investigate whether the sympathetic stimulation of BAT, as assessed with a 123I-metaiodobenzylguanidine single-photon emission computed tomography computed tomography scan, differs between lean and obese individuals, as an explanation for the diminished metabolic brown adipose tissue activity in obese subjects. The investigators hypothesis is that sympathetic nervous system activity in the obese is diminished as compared to their leaner counterparts as an explanation for the diminished metabolic brown adipose tissue activity in the obese.
Detailed description
The sympathetic nervous system is the primary activator of Brown Adipose Tissue. Obese humans are known to have less metabolically active brown adipose tissue as compared to their leaner counterparts. The reason for this diminished metabolic brown adipose tissue activity is unknown. However, a lower sympathetic nervous system activation to brown adipose tissue in the obese might explain a diminished metabolic brown adipose tissue. Therefore, in this study, both the sympathetic nervous system activation to brown adipose tissue and the metabolic activity will be measured in lean and obese subjects. sympathetic nervous system activity will be measured using 123I-metaiodobenzylguanidine single-photon emission computed tomography scans, metabolic activity will be measured using 18F- fluorodeoxyglucose positron emission tomography CT scans.
Interventions
OTHER18F- fluorodeoxyglucose-positron emission tomography Computed Tomography scan and 123I-metaiodobenzylguanidine-single-photon emission computed tomography scan
Sponsors
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
* Male * Caucasian origin * Subjects should be able and willing to give informed consent * 18-40 years old * BMI range of 19-25 kg/m2 (lean study subjects) or 28-40 kg/m2 (obese study subjects)
Exclusion criteria
* Renal failure (creatinine\>135mmol/l) * Daily use of prescription medication
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Difference in sympathetic stimulation to BAT between lean and obese individuals | Participants will be followed for a mean duration of 2 weeks (the maximal time period between the two scans) The outcome measurements will be assessed when the last subject has been scanned approximately one year after starting the trial |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Difference in correlation between sympathetic stimulation of BAT as assessed with 123I-MIBG SPECT scans and metabolic BAT activity as assessed with 18F-Fluorodeoxyglucose(FDG)- positron emission tomography(PET)-CT scan in lean and obese individuals | Participants will be followed for a mean duration of 2 weeks (the maximal time period between the two scans) The outcome measurements will be assessed when the last subject has been scanned approximately one year after starting the trial. | The difference in correlation between sympathetic stimulation of BAT and metabolic BAT activity between lean and obese individuals. |
Countries
Netherlands
Outcome results
None listed